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A B S T R A C T   
Glycogen storage disease type 1a (GSD1a) is an autosomal recessive disorder caused by mutations of the glucose-6-phosphatase (G6PC) gene. Mutations of the G6PC 
gene lead to excessive accumulation of glycogen in the liver, kidney, and intestinal mucosa due to the deficiency of microsomal glucose-6-phosphatase. Human 
induced pluripotent stem cells (iPSCs) enable the production of patient-derived hepatocytes in culture and are therefore a promising tool for modeling GSD1a. Here, 
we report the establishment of human iPSCs from a GSD1a patient carrying a G6PC mutation (c.648G > T; p.Leu216 = ).   
1. Resource Table:  
Unique stem cell line 
identifier 
BRCi009-A 
Alternative name(s) of 
stem cell line 
HPS3926 
Institution RIKEN BioResource Research Center (BRC), Kyoto, 
Japan 




Type of cell line iPSC 
Origin Human 
Additional origin info Applicable for human iPSC 
Age: 31 
Sex: female 
Ethnicity if known: Japanese 
Cell Source Fibroblasts 
Clonality Clonal 
Method of reprogramming Sendai virus vectors (KLF4, OCT3/4, SOX2, c-Myc) 
Genetic Modification None 
Type of Modification None 
Associated disease Glycogen storage disease type 1a (GSD1a) 
Gene/locus G6PC gene/Chromosome 17 
Method of modification Not available 
Name of transgene or 
resistance 
Not available 
(continued on next column)  
(continued ) 






Date archived/stock date January 2020 
Cell line repository/bank RIKEN BioResource Research Center (BRC), Japan 
http://en.brc.riken.jp/index.htmlcellbank. 
brc@riken.jp 
Ethical approval Ethics Committee of the RIKEN BioResource Research 
Center (Approval No. Tsukuba 29–1)   
1.1. Resource utility 
GSD1a is an autosomal recessive disorder caused by mutations of the 
G6PC gene. The disease pathophysiology is not well understood. iPSCs 
were generated from a GSD1a patient with a G6PC gene mutation 
(c.648G > T; p.Leu216 = ). This disease-specific iPSC line will be used to 
study the pathological mechanisms of GSD1a (Table 1). 
1.2. Resource details 
Glycogen storage disease type 1a (GSD1a) is an autosomal recessive 
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disorder caused by mutations of the glucose-6-phosphatase (G6PC) 
gene. Mutations of the G6PC gene lead to excessive accumulation of 
glycogen in the liver, kidney, and intestinal mucosa due to the deficiency 
of microsomal glucose-6-phosphatase (Akanuma et al., 2000; Kanungo 
et al., 2018). The clinical manifestations of GSD1a include short stature, 
doll-like face, hepatomegaly, hypoglycemia, hyperuricemia, and lactic 
acidemia. However, the disease pathophysiology is largely unknown. 
GSD 1a-specific iPSCs have the potential for investigation of the path-
ophysiological mechanisms of GSD 1a. We established and characterized 
an iPSC line from a patient with attenuated GSD 1a who carried a G6PC 
gene mutation (c.648G > T; p.Leu216 = ). GSD1a-specific iPSCs were 
generated from fibroblasts of the GSD1a patient using Sendai virus 
vectors carrying reprogramming factors (Fujie et al., 2014). The GSD1a- 
specific iPSCs (HPS3926) had a human ES cell-like morphology 
(Fig. 1A). The iPSCs were immunocytologically positive for the plurip-
otency markers NANOG and SSEA4 (Fig. 1A); 99.8% of the iPSCs were 
positive for the pluripotency marker SSEA4 by flow cytometry (Fig. 1B). 
The capacity of the iPSCs to differentiate into the three germ layers was 
confirmed using an in vitro embryoid body (EB) formation assay (Fig. 1C; 
βIII-tubulin, ectoderm; smooth muscle actin (SMA), mesoderm; SOX17, 
endoderm). Furthermore, the iPSCs retained a normal karyotype 
(Fig. 1D), and carried the G6PC gene mutation (Fig. 1E). The identity of 
the cell line was verified with an STR analysis (information available 
from the authors). Mycoplasma contamination was not detected in the 
cell culture (Supplementary Fig. 1). Established iPSCs were able to 
differentiate into hepatocytes that showed positive staining for alpha- 
fetoprotein (AFP) (Fig. 1F) 
2. Materials and methods 
2.1. Ethics statement 
The generation and use of human iPSCs was approved by the Ethics 
Committees of RIKEN BioResource Research Center (BRC). Formal 
informed consent was obtained from the patient. 
2.2. Generation of iPSCs 
Human cDNAs for reprogramming factors were transduced into the 
fibroblasts using Sendai virus vectors (KLF4, OCT3/4, SOX2, c-Myc). 
The generated iPSCs were cultured under feeder-free conditions on 
iMatrix-511 (Nippi, Tokyo, Japan)-coated plates with StemFit (AK02N, 
Ajinomoto, Tokyo, Japan) (Nakagawa et al., 2015). 
2.3. Karyotyping 
A G-band analysis was performed by LSI Medience (Tokyo, Japan) to 
determine the karyotype of the iPSC line at passage number 6. Twenty 
metaphase plates were analyzed. 
2.4. Genotyping 
Genomic DNA from undifferentiated iPSCs at passage number 27 was 
extracted using a PureLink Genomic DNA Mini Kit (Invitrogen, Thermo 
Fisher Scientific) and amplified by PCR using the enzyme KOD Plus Neo 
(TOYOBO, Japan). The targeted PCR product was directly sequenced. 
2.5. In vitro three germ layer differentiation assay 
Embryoid bodies (EBs) were produced by culturing 9,000 dissociated 
iPSCs in DMEM/F12 medium supplemented with 20% knockout serum 
replacement (KSR), 2 mM L-glutamine, 0.1 mM non-essential amino acid 
(NEAA) supplement, 0.1 mM 2-mercaptoethanol (Thermo Fisher Scien-
tific), 10 μM Y-27632 (Nacalai Tesque, Kyoto, Japan) for 11 days, fol-
lowed by culture in DMEM containing 10% FBS (Thermo Fisher 
Scientific) on a Matrigel (BD Bioscience)-coated tissue culture plate for 
7 days. 
2.6. Hepatocyte differentiation 
Dissociated iPSCs were plated onto a Matrigel coated plate, and 
cultured in RPMI 1640 Medium, GlutaMAX™ supplement, with B27 
supplement (Minus Vitamin A: B27VitA-) (Thermo Fisher Scientific), 5% 
KSR, 1% DMSO, 100 ng/ml of human recombinant Activin A (Wako 
Pure Chemical Industries Ltd.), 3 μM CHIR99021 (STEMCELL Technol-
ogies) and 10 μM Y-27632 for 3 days. The cells were then cultured in 
RPMI 1640 medium, GlutaMAX™ supplement with B27VitA-, 5% KSR, 
1% DMSO, 2 mM valproic acid, 20 ng/ml of BMP4 and 20 ng/ml of FGF4 
(Wako Pure Chemical Industries Ltd.) for 3 days. Next, the cells were 
cultured in RPMI1640 medium, GlutaMAX™ supplement with B27VitA-, 
5% KSR, 20 ng/ml hepatocyte growth factor (HGF; R&D Systems) and 
2 mM valproic acid for 4 days. Finally, the cells were cultured in hepa-
tocyte culture medium (Lonza) with 20 ng/ml of oncostatin M (Wako 
Pure Chemical Industries Ltd.) for 5 days. 
2.7. Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde (Nacalai Tesque). The fixed 
cells were incubated with blocking buffer composed of PBS containing 
5% Blocking-One-histo (Nacalai Tesque) and 0.1% Triton-X 100 
(Nacalai Tesque). Nuclei were stained with DAPI (Invitrogen, Thermo 
Table 1 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography Normal Fig. 1 panel A 







Fig. 1 panel A 
Quantitative analysis 
(Flow cytometry) 




Fig. 1 panel B 




Fig. 1 panel D 
Identity Microsatellite PCR 
(mPCR) 
Not performed Not performed 






(c.648 G > T, p. 
Leu216 = ) 
Fig. 1 panel E 
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Fig. 1 panel C 
Donor 
screening 






Blood group genotyping Not performed Not performed 
HLA tissue typing Not performed Not performed  
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Fisher Scientific). Images were obtained with a BZ-X710 microscope 
(Keyence, Osaka, Japan). 
2.8. Flow cytometry 
The iPSCs were dissociated with Accumax solution (Sigma Aldrich, 
St. Louis, MO). The dissociated iPSCs were suspended in PBS containing 
2% FBS (Stain buffer, BD Bioscience, San Jose, CA) at a density of 
1.0 × 106 cells/ml. The cells were stained for 30 min on ice and analyzed 
using a FACS Aria (BD Bioscience). The Alexa Fluor 647-labeled anti-
bodies used for flow cytometry are listed in Table 2. The FlowJo soft-
ware program (ver.10, FLOWJO, BD Bioscience) was used for data 
analysis. 
2.9. STR analysis 
STR analysis was performed using a PowerPlex® 16 System (Prom-
ega, Madison, WI). 
2.10. Mycoplasma test 
iPSC culture medium was tested by staining with Hoechst33258 
(Thermo Fisher Scientific) after 6 days of co-culture with VERO cells 
(RCB0001, RIKEN BRC Cell Bank) as mycoplasma negative indicator 
cells. Nested-PCR was performed using AmpliTaq Gold 360 DNA Poly-
merase (Thermo Fisher Scientific) to detect mycoplasma contamination. 
Fig. 1.  
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Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.scr.2020.102095. 
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Table 2 
Reagent details.  
Antibodies used for immunocytochemistry/flow-cytometry  
Antibody Dilution Company Cat # and 
RRID 
Pluripotency marker Mouse anti-Stage- 
Specific Embryonic 
Antigen-4 (SSEA-4) 
1:1,000 Millipore Cat# 
MAB4304 
RRID: AB_177629 
Pluripotency marker Rabbit anti-NANOG 1:500 Cell Signaling 






























1:1,000 Sigma-Aldrich Cat# 
A8452 RRID: 
AB_258392 
Secondary antibody Goat Anti-Mouse IgG 
Alexa Fluor Plus 488 
1:1,000 Thermo Fisher 
Scientific Cat# A32723 
RRID: AB_2633275 
Secondary antibody Goat Anti-Rabbit IgG 
Alexa Fluor 488 
1:1,000 Thermo Fisher 
Scientific Cat# A11034 
RRID: AB_2576217 
Secondary antibody Chicken Anti-Mouse 
IgG Alexa Fluor 647 
1:1,000 Thermo Fisher 
Scientific Cat# A21463 
RRID: AB_2535869  
Primers  
Target Forward/Reverse primer (5′-3′) 
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